Aerie Pharmaceuticals, Inc. — Revenue by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/96f33a89-0d6c-4415-bac2-f89afbab2a8e/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2021 | $194.1M | 2021-01-01 – 2021-12-31 | evidence 0001337553-22-000013 |
| FY 2020 | $83.1M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-003345 |
| FY 2019 | $69.9M | 2019-01-01 – 2019-12-31 | evidence 0001628280-20-002027 |
| FY 2018 | $24.2M | 2018-01-01 – 2018-12-31 | evidence 0001628280-19-002369 |
| FY 2017 | $0 | 2017-01-01 – 2017-12-31 | evidence 0001628280-19-002369 |
| FY 2016 | $0 | 2016-01-01 – 2016-12-31 | evidence 0001628280-19-002369 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Aerie Pharmaceuticals, Inc. — all facts · Net Income · Operating Income